UBS AM’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-47,452
| Closed | -$503K | – | 2624 |
|
|
2025
Q1 | $503K | Sell |
47,452
-4,737
| -9% | -$50.2K | ﹤0.01% | 2502 |
|
|
2024
Q4 | $886K | Sell |
52,189
-153,567
| -75% | -$2.61M | ﹤0.01% | 2419 |
|
|
2024
Q3 | $4.78M | Buy |
205,756
+204
| +0.1% | +$4.74K | ﹤0.01% | 1595 |
|
|
2024
Q2 | $5.01M | Buy |
205,552
+25,154
| +14% | +$613K | ﹤0.01% | 1486 |
|
|
2024
Q1 | $6.09M | Buy |
180,398
+154,444
| +595% | +$5.22M | ﹤0.01% | 1171 |
|
|
2023
Q4 | $818K | Buy |
25,954
+2,707
| +12% | +$85.4K | ﹤0.01% | 2131 |
|
|
2023
Q3 | $594K | Buy |
23,247
+6,352
| +38% | +$162K | ﹤0.01% | 2223 |
|
|
2023
Q2 | $405K | Hold |
16,895
| – | – | ﹤0.01% | 2386 |
|
|
2023
Q1 | $405K | Buy |
+16,895
| New | +$405K | ﹤0.01% | 2386 |
|
|
2022
Q2 | – | Sell |
-17,692
| Closed | -$477K | – | 2694 |
|
|
2022
Q1 | $477K | Hold |
17,692
| – | – | ﹤0.01% | 2479 |
|
|
2021
Q4 | $655K | Sell |
17,692
-1,253
| -7% | -$46.4K | ﹤0.01% | 2431 |
|
|
2021
Q3 | $905K | Buy |
18,945
+269
| +1% | +$12.9K | ﹤0.01% | 2221 |
|
|
2021
Q2 | $632K | Buy |
18,676
+2,451
| +15% | +$82.9K | ﹤0.01% | 2442 |
|
|
2021
Q1 | $670K | Buy |
16,225
+1,625
| +11% | +$67.1K | ﹤0.01% | 2278 |
|
|
2020
Q4 | $633K | Buy |
14,600
+300
| +2% | +$13K | ﹤0.01% | 2206 |
|
|
2020
Q3 | $613K | Buy |
14,300
+3,200
| +29% | +$137K | ﹤0.01% | 2042 |
|
|
2020
Q2 | $519K | Buy |
+11,100
| New | +$519K | ﹤0.01% | 2117 |
|